Maynard Um
-
-
-
-
-
-
-
Spyre (SYRE) Reiterated at Buy by Stifel on Topline Results From RA PoC Sub-Study
-
-
-
-
-
-
-
Spyre reports positive phase 2 trial results for ulcerative colitis drug
-
-
-
-
-
-
-
Syre Therapeutics (SYPR) PT Raised to $106 at Leerink Partners, 'initial SKYLINE results represent best-case data for SPY001'
-
-
-
-
-
-
-
TD Cowen on Spyre (SYRE): 'we expect these data to further raise the ceiling for Spyre's future combos'
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Spyre (SYRE): 'today's update reflects SYRE's strong clinical execution'
-
-
-
-
-
-
-
Spyre (SYRE) PT Lowered to $70 at Stifel
-
-
-
-
-
-
-
Spyre Therapeutics (SYRE) Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs
-
466,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


